# SPAGO: Sirolimus Paclitaxel Angiographic Gain Objective

Study · id `cardio:ct-nct06373601` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06373601](<https://clinicaltrials.gov/study/NCT06373601>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06373601

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 140 participants.

## Technical summary

Registry record NCT06373601. Randomized; no masking; primary purpose treatment. Start 2024-09-05 (actual); primary completion 2027-08-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 140 participants (planned count; ClinicalTrials.gov record NCT06373601, source copy `cardio:ctgov-nct06373601-2025-12-03`, retrieved 2026-10-26)
- Started: 2024-09-05 (actual) (ClinicalTrials.gov record NCT06373601, source copy `cardio:ctgov-nct06373601-2025-12-03`, retrieved 2026-10-26)
- Primary completion: 2027-08-01 (anticipated) (ClinicalTrials.gov record NCT06373601, source copy `cardio:ctgov-nct06373601-2025-12-03`, retrieved 2026-10-26)
- Completion: 2027-08-01 (anticipated) (ClinicalTrials.gov record NCT06373601, source copy `cardio:ctgov-nct06373601-2025-12-03`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT06373601, source copy `cardio:ctgov-nct06373601-2025-12-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06373601-2025-12-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: SPAGO: Sirolimus Paclitaxel Angiographic Gain Objective
- Acronym: SPAGO
- Condition: Coronary Artery Disease
- Condition: Stenosis Coronary
- Condition: Coronary Artery Lesion
- Condition: Percutaneous Coronary Intervention
- Intervention (Device): sirolimus-eluting balloon (Selution)
- Intervention (Device): paclitaxel-eluting balloon (SeQuent Please Neo)
- Lead sponsor: Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS (`cardio:org-fondazione-evidence-per-attivita-e-ricerche-cardiovascolari-aa9be1`)

## Provenance

Content hash: 9a0524cfe5ffb8c9453132a6ab0fa659dd438fbe3e65f49cbc730e19de1115f1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
